Can a Clot-Removing device ease acute pulmonary embolism?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient is ≥ 18 and ≤ 90 years old 2. Clinical signs and symptoms consistent with acute PE for \< 14 days 3. CTA evidence of proximal PE 4. RV/LV ratio \> 0.9 5. Systolic BP ≥90 mmHg without the need for vasopressors 6. Stable heart rate (HR) \< 130 BPM prior to procedure 7. Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment 8. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures Exclusion Criteria: 1. Prior PE \< 180 days from index procedure 2. Thrombolytic use \< 30 days prior to baseline CTA 3. Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) \>70 mmHg by right heart catheterization 4. FiO2 requirement \>40% or \>6 LPM to keep oxygen saturation \>90% 5. Hematocrit \<28% 6. Platelets count \<100,000/µL 7. Serum creatinine \>1.8 mg/dL 8. International normalized ratio (INR) \>3 9. Major trauma injury severity score (ISS) \>15 prior to screening assessment 10. Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment 11. Cardiovascular or pulmonary surgery within 7 days of index procedure 12. Actively progressing cancer treated by chemotherapeutics 13. Known bleeding diathesis or coagulation disorder 14. Left bundle branch block 15. History of severe or chronic pulmonary arterial hypertension 16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30% 17. History of decompensated heart failure 18. History of underlying lung disease that is oxygen dependent 19. History of chest irradiation 20. History of heparin-induced thrombocytopenia (HIT) 21. Contraindication to systemic or therapeutic doses of anticoagulants 22. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated 23. Imaging evidence or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention 24. Life expectancy \<90 days, as determined by investigator such as stage 4 cancer, frailty or severe COVID infections 25. Female who is pregnant or nursing 26. Current participation in another investigational drug or device treatment study.